Daiichi Sankyo Espha Goes on AG Spree as It Wins Nod for 7 Major Brands

By Reiji Anasako Daiichi Sankyo Espha, a generic subsidiary of Daiichi Sankyo, clinched approval for authorized generic (AG) versions of seven major brands on February 15, including the parent company’s angiotensin receptor blocker (ARB) Olmetec (olmesartan) and other makers’ flagship...read more